Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of early periprosthetic bone loss after total hip arthroplasty
2006-004294-10Phase 2Active
- Sponsor
- IMAS
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Aseptic loosening (AL) and osteoporosis comparing Zoledronic acid (Aclasta) with Placebo (2 arms). Primary endpoint: Periprosthetic bone mass by bone densitometry. Started Aug 2008; status: active.
02
Drugs
zoledronic acid
03
Conditions
Aseptic loosening (AL)osteoporosis
Beyond the preview
Go deeper on 2006-004294-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004294-10.